Metoclopramide Tablet
FDA Recall NDC 0093-2203
FDA Enforcement Report: View Recall Date, Reasons, and Safety Status
Active & Historical Enforcement Reports
The FDA has identified 1 recorded enforcement report(s) associated with Metoclopramide (NDC 0093-2203). A significant event, classified as Class II, was initiated on May 23, 2025 by Teva Pharmaceuticals Usa, Inc.. The reported reason for this action was: "Presence of foreign tablets/capsules."
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
Reported Recall Events
Class II Ongoing
Presence of foreign tablets/capsules.
May 23, 2025
Jul 02, 2025
36612 cartons
Recall Profile & Regulatory Data
Event ID
96919
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
Teva Pharmaceuticals USA, Inc
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
USA Nationwide
Product Description
Metoclopramide Tablets, USP 10 mg, 100-count bottle, Rx only, Manufactured in Croatia by Pliva Hrvatska, d.o.o., Zageb, Croatia, Manufactured for Teva Pharmaceuticals, Parsippany, NJ 07054, NDC 0093-2203-01.
Batch or Lot Expiration Information
Lot# : 5420094, Exp 09/30/2027
Affected Packages Involved in this Recall
0093-2204-01Product
0093-2204-05Product
0093-2203-01Product
0093-2203-05Product
0093-2203-10Product
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.
